SCHEMBL26922641

SCHEMBL26922641

CC(C)(C)OC(=O)N1C2CC(C#N)CC1C2

nearest known ligand 0.54

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
CHRM2 P08172 1/20 0.54
CHRM1 P11229 1/20 0.54
CHRM3 P20309 1/20 0.54
CTSK P43235 1/20 0.41
DPP4 P27487 1/20 0.40
PREP P48147 3/20 0.40
GPR119 Q8TDV5 3/20 0.39
HPGD P15428 1/20 0.39
USP2 O75604 1/20 0.38
SMN1; SMN2 Q16637 1/20 0.38
RECQL P46063 1/20 0.37
AR P10275 1/20 0.37
HSD11B1 P28845 1/20 0.36
NR1H2 P55055 1/20 0.36
MEN1 O00255 1/20 0.36
ALDH1A1 P00352 1/20 0.36
MAPT P10636 1/20 0.36
KMT2A Q03164 1/20 0.36
EPHX2 P34913 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16116400 0.92 CHRM2 (0.66) CHRM2CHRM1CHRM3CTSKDPP4
SCHEMBL16135448 0.92 CHRM2 (0.66) CHRM2CHRM1CHRM3CTSKDPP4
SCHEMBL16115131 0.92 CHRM2 (0.66) CHRM2CHRM1CHRM3CTSKDPP4
SCHEMBL796116 0.92 CHRM2 (0.66) CHRM2CHRM1CHRM3CTSKDPP4
SCHEMBL31341741 0.88 CHRM2 (0.49) CHRM2CHRM1CHRM3CTSKDPP4
Potassium Ion SCHEMBL30567066 0.86 CHRM2 (0.59) CHRM2CHRM1CHRM3CTSKDPP4
SCHEMBL31398492 0.83 CHRM2 (0.46) CHRM2CHRM1CHRM3CTSKDPP4
SCHEMBL16115751 0.81 CHRM2 (0.44) CHRM2CHRM1CHRM3CTSKDPP4
SCHEMBL17507219 0.81 CHRM2 (0.44) CHRM2CHRM1CHRM3CTSKDPP4
SCHEMBL16115094 0.81 CHRM2 (0.44) CHRM2CHRM1CHRM3CTSKDPP4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4746963-A1 MACROCYCLES FOR THE TREATMENT OF AUTOIMMUNE DISEASE F. Hoffmann-La Roche AG (CH) 2026-05-27 EP disclosed
US-20250361234-A1 COMPOUNDS, COMPOSITIONS, AND METHODS NICO THERAPEUTICS INC (US) 2025-11-27 US disclosed
EP-4598927-A2 COMPOUNDS, COMPOSITIONS, AND METHODS Tenvie Therapeutics Inc. (US) 2025-08-13 EP disclosed
EP-4536637-A2 COMPOUNDS, COMPOSITIONS, AND METHODS Nico Therapeutics, Inc. (US) 2025-04-16 EP disclosed
WO-2025017045-A1 MACROCYCLES FOR THE TREATMENT OF AUTOIMMUNE DISEASE F. HOFFMANN-LA ROCHE AG (CH) 2025-01-23 WO disclosed
WO-2024077273-A2 COMPOUNDS, COMPOSITIONS, AND METHODS DENALI THERAPEUTICS INC. (US) 2024-04-11 WO disclosed
WO-2023240084-A2 COMPOUNDS, COMPOSITIONS, AND METHODS DENALI THERAPEUTICS INC. (US) 2023-12-14 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250361234-A1 COMPOUNDS, COMPOSITIONS, AND METHODS SARM1, SARS1, TIAM1 CHRM2 4765/4885CHRM1 4281/4885CHRM3 4483/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.